From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||146.6 kDa|
This drug was developed by Novartis Pharma AG.
Adverse drug effects
|This section is empty. You can help by adding to it. (October 2014)|
- Statement On A Nonproprietary Name Adopted By The USAN Council - Ligelizumab, American Medical Association.
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|